Nina Helbekkmo
Tromso, Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Gut microbiota alterations in patients with non-small-cell lung cancer undergoing chemoradiotherapy.
Gut microbiota alterations in patients with non-small-cell lung cancer undergoing chemoradiotherapy.
Journal: Molecular oncology
Published: March 23, 2026
How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab?
Journal: Acta oncologica (Stockholm, Sweden)
Published: November 12, 2025
Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab.
Journal: Frontiers in oncology
Published: August 07, 2025
Too much or too little? The trajectory of systemic anti-cancer treatment throughout the last year of life of lung cancer patients in Norway.
Journal: BJC reports
Published: May 20, 2025
High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC: Final Survival Data, Long-Term Toxicity, and Relapse Patterns in a Randomized, Open-Label, Phase II Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 14, 2025
Small Cell Lung Cancer in Norway: Patterns of Care by Health Region and Survival Trends.
Journal: Clinical lung cancer
Published: December 21, 2023
Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial.
Journal: Molecular oncology
Published: May 20, 2022
Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC.
Journal: Acta oncologica (Stockholm, Sweden)
Published: June 17, 2020
Increase in curative treatment and survival of lung cancer in Norway 2001-2016.
Journal: European journal of epidemiology
Published: February 21, 2019
Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 15, 2018
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain-a model-based analysis.
Journal: ESMO open
Published: May 24, 2017
How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial.
Journal: Clinical lung cancer
Published: June 17, 2014
Last Updated: 09/26/2026